NASDAQ:ADMS Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ADMS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.22▼$8.2250-Day Range$7.97▼$8.2352-Week Range$4.02▼$9.15VolumeN/AAverage Volume692,487 shsMarket Capitalization$376.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Adamas Pharmaceuticals alerts: Email Address Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Read More Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. ADMS Stock News HeadlinesApril 7, 2023 | benzinga.comSurvalent, Electroval win bid to provide ICE "first of its kind" ADMS and DERMS platformApril 7, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market 2023 | Global Industry Report Forecast 2029May 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 30, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market LATEST REPORT 2023 to 2030March 3, 2023 | investing.comAdamas One Corp (JEWL)March 1, 2023 | marketwatch.com2023 Advanced Distribution Management System (ADMS) Market: Top Growing Regions for Business Leaders by 2029March 1, 2023 | marketwatch.comAdvanced Distribution Management System (ADMS) Market 2023 | Global Industry Report Forecast 2029February 24, 2023 | marketwatch.comAdvanced Distributed Management System (ADMS) Market Is Booming Worldwide Forecast 2023-2029May 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).January 14, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market Future Trends Demand 2023, and Forecast to 2029May 25, 2022 | insidermonkey.com8 Stocks to Buy According to Devesh Gandhi’s SilverArc CapitalNovember 24, 2021 | finance.yahoo.comSupernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsNovember 4, 2021 | finance.yahoo.comSupernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call TranscriptNovember 2, 2021 | finance.yahoo.comHow Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?November 1, 2021 | bizjournals.comEast Bay drug maker's potential sale brings lawsuits, job cutsOctober 28, 2021 | finance.yahoo.comWill Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should KnowOctober 27, 2021 | finance.yahoo.comADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the FirmOctober 21, 2021 | finance.yahoo.comWhy Supernus' Acquisition of Adamas Is a Smart MoveOctober 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing InvestigationsOctober 18, 2021 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, AZPN, GSKY, GWB; Shareholders are Encouraged to Contact the FirmOctober 16, 2021 | prnewswire.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMSOctober 15, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMSOctober 14, 2021 | finance.yahoo.comADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the FirmOctober 13, 2021 | businesswire.comADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas ...October 12, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Adamas Pharmaceuticals, Inc. MergerOctober 12, 2021 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the FirmOctober 11, 2021 | businesswire.comAdamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...See More Headlines Receive ADMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADMS CUSIPN/A CIK1328143 Webwww.adamaspharma.com Phone(510) 450-3500Fax510-428-0519Employees138Year Founded2002Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,400,000.00 Net Margins-71.11% Pretax Margin-71.11% Return on EquityN/A Return on Assets-42.96% Debt Debt-to-Equity Ratio21.25 Current Ratio4.53 Quick Ratio4.17 Sales & Book Value Annual Sales$74.46 million Price / Sales5.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-17.49Miscellaneous Outstanding Shares45,787,000Free Float37,133,000Market Cap$376.37 million OptionableOptionable Beta2.82 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesNeil F. McFarlaneChief Executive Officer & DirectorChristopher B. PrentissChief Financial OfficerAdrian QuartelChief Medical OfficerVijay ShreedharChief Commercial OfficerJill M. JeneHead-Corporate Development & StrategyKey CompetitorsRevance TherapeuticsNASDAQ:RVNCAmarinNASDAQ:AMRNLexicon PharmaceuticalsNASDAQ:LXRXEsperion TherapeuticsNASDAQ:ESPRMereo BioPharma GroupNASDAQ:MREOView All Competitors ADMS Stock Analysis - Frequently Asked Questions How were Adamas Pharmaceuticals' earnings last quarter? Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its quarterly earnings data on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to the consensus estimate of $25.07 million. What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO? 2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adamas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV). This page (NASDAQ:ADMS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
